Empirical use of fluoroquinolones improves the survival of critically ill patients with tuberculosis mimicking severe pneumonia

Critical Care

Volumn 16, Issue 5, 2012, Pages

  Tseng, Yu Tzu ^a   Chuang, Yu Chung ^a   Shu, Chin Chung ^a   Hung, Chien Ching ^a   Hsu, Chiung Fang ^a   Wang, Jann Yuan ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CIPROFLOXACIN; ETHAMBUTOL; ISONIAZID; LEVOFLOXACIN; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; SULTAMICILLIN; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC THERAPY; APACHE; ARTICLE; BACTEREMIA; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DISEASE SEVERITY; FEMALE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INTENSIVE CARE; INTENSIVE CARE UNIT; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SPUTUM CULTURE; STATISTICAL SIGNIFICANCE; SURVIVAL; AGED; COMMUNITY-ACQUIRED INFECTIONS; DIFFERENTIAL DIAGNOSIS; ENDEMIC DISEASE; EPIDEMIOLOGY; LENGTH OF STAY; PNEUMONIA; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; TAIWAN; TUBERCULOSIS, PULMONARY;

AGED; ANTI-BACTERIAL AGENTS; ANTITUBERCULAR AGENTS; APACHE; BACTEREMIA; COMMUNITY-ACQUIRED INFECTIONS; DIAGNOSIS, DIFFERENTIAL; ENDEMIC DISEASES; FEMALE; FLUOROQUINOLONES; HUMANS; INTENSIVE CARE UNITS; LENGTH OF STAY; MALE; PNEUMONIA; RETROSPECTIVE STUDIES; TAIWAN; TUBERCULOSIS, PULMONARY;

EID: 84867748403     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc11839     Document Type: Article

References (39)

1. Marti C, Garin N, Grosgurin O, Poncet A, Combescure C, Carballo S, Perrier A. Prediction of severe community-acquired pneumonia: a systematic review and meta-analysis. Crit Care 2012, 16:R141. 10.1186/cc11447, 22839689.
2. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Musher DM, Niederman MS, Torres A, Whitney CG. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44:S27-S72. 10.1086/511159, 17278083.
3. Frei CR, Labreche MJ, Attridge RT. Fluoroquinolones in community-acquired pneumonia: guide to selection and appropriate use. Drugs 2011, 71:757-770. 10.2165/11585430-000000000-00000, 21504252.
4. Watkins RR, Lemonovich TL. Diagnosis and management of community-acquired pneumonia in adults. Am Fam Physician 2011, 83:1299-1306.
5. Scott JA, Hall AJ, Muyodi C, Lowe B, Ross M, Chohan B, Mandaliya K, Getambu E, Gleeson F, Drobniewski F, Marsh K. Aetiology, outcome, and risk factors for mortality among adults with acute pneumonia in Kenya. Lancet 2000, 355:1225-1230. 10.1016/S0140-6736(00)02089-4, 10770305.
6. Liam CK, Pang YK, Poosparajah S. Pulmonary tuberculosis presenting as community-acquired pneumonia. Respirology 2006, 11:786-792. 10.1111/j.1440-1843.2006.00947.x, 17052309.
7. Cremades R, Rodriquez JC, Garcia-Pachón E, Galiana A, Ruiz-García M, López P, Royo G. Comparison of the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in an in vitro experimental model. J Antimicrob Chemother 2011, 66:2281-2283. 10.1093/jac/dkr281, 21733966.
8. Yew WW, Chan CK, Chau CH, Tam CM, Leung CC, Wong PC, Lee J. Outcome of patients with multi-drug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 2000, 117:744-751. 10.1378/chest.117.3.744, 10713001.
9. Ziganshina LE, Squire SB. Fluoroquinolones for treating tuberculosis. Cochrane Database Syst Rev 2008, 1:CD004795.
10. Dooley KE, Golub J, Goes FS, Merz WG, Sterling TR. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis 2002, 34:1607-112. 10.1086/340618, 12032896.
11. Wang JY, Hsueh PR, Jan IS, Lee LN, Liaw YS, Yang PC, Luh KT. Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax 2006, 61:903-908. 10.1136/thx.2005.056887, 2104756, 16809417.
12. Devasia RA, Blackman A, Gebretsadik T, Griffin M, Shintani A, May C, Smith T, Hooper N, Maruri F, Warkentin J, Mitchel E, Sterling TR. Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med 2009, 180:365-370. 10.1164/rccm.200901-0146OC, 2731810, 19483111.
13. Long R, Chong H, Hoeppner V, Shanmuganathan H, Kowalewska-Grochowska K, Shandro C, Manfreda J, Senthilselvan A, Elzainy A, Marrie T. Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosis. Clin Infect Dis 2009, 48:1354-1360. 10.1086/598196, 19348594.
14. Golub JE, Bur S, Cronin WA, Gange S, Sterling TR, Oden B, Baruch N, Comstock GW, Chaisson RE. Impact of empiric antibiotics and chest radiograph on delays in the diagnosis of tuberculosis. Int J Tuberc Lung Dis 2005, 9:392-397.
15. Yoon YS, Lee HJ, Yoon HI, Yoo CG, Kim YW, Han SK, Shim YS, Yim JJ. Impact of fluoroquinolones on the diagnosis of pulmonary tuberculosis initially treated as bacterial pneumonia. Int J Tuberc Lung Dis 2005, 9:1215-1219.
16. van den Boogaard J, Semvua HH, van Ingen J, Mwaigwisya S, van der Laan T, van Soolingen D, Kibiki GS, Boeree MJ, Aarnoutse RE. Low rate of fluoroquinolone resistance in Mycobacterium tuberculosis isolates from northern Tanzania. J Antimicrob Chemother 2011, 66:1810-1814. 10.1093/jac/dkr205, 21642290.
17. Park IN, Hong SB, Oh YM, Lim CM, Lee SD, Lew WJ, Koh Y, Kim WS, Kim DS, Kim WD, Shim TS. Impact of short-term exposure to fluoroquinolones on ofloxacin resistance in HIV-negative patients with tuberculosis. Int J Tuberc Lung Dis 2007, 11:319-324.
18. Wang JY, Lee LN, Lai HC, Wang SK, Jan IS, Yu CJ, Hsueh PR, Yang PC. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. J Antimicrob Chemother 2007, 59:860-865. 10.1093/jac/dkm061, 17412727.
19. Wang JY, Lee LN, Hsueh PR. Factors changing the manifestation of pulmonary tuberculosis. Int J Tuberc Lung Dis 2005, 9:777-783.
20. Lee PL, Jerng JS, Chang YL, Chen CF, Hsueh PR, Yu CJ, Yang PC, Luh KT. Patient mortality of active pulmonary tuberculosis requiring mechanical ventilation. Eur Respir J 2003, 22:141-147. 10.1183/09031936.03.00038703, 12882464.
21. Wang JY, Hsueh PR, Jan IS, Lee LN, Liaw YS, Yang PC, Luh KT. The effect of smoking on tuberculosis: different patterns and poorer outcomes. Int J Tuberc Lung Dis 2007, 11:143-149.
22. Wang JY, Hsueh PR, Wang SK, Jan IS, Lee LN, Liaw YS, Yang PC, Luh KT. Disseminated tuberculosis: a 10-year experience in a medical center. Medicine (Baltimore) 2007, 86:39-46.
23. Center for Disease Control of Taiwan Statistics of Communicable Diseases and Surveillance Report in Taiwan Area, 2009 2009, Taipei, Taiwan: Center for Disease Control, Center for Disease Control of Taiwan., http://www2.cdc.gov.tw/public/Data/912311651471.pdf
24. Wang JY, Lee LN, Chou CS, Huang CY, Wang SK, Lai HC, Hsueh PR, Luh KT. Performance assessment of a nested-PCR assay (the RAPID BAP-MTB) and the BD ProbeTec ET system for detection of Mycobacterium tuberculosis in clinical specimens. J Clin Microbiol 2004, 42:4599-4603. 10.1128/JCM.42.10.4599-4603.2004, 522346, 15472315.
25. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989, 11:954-963. 10.1093/clinids/11.6.954, 2690289.
26. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818-829. 10.1097/00003246-198510000-00009, 3928249.
27. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996, 22:707-710. 10.1007/BF01709751, 8844239.
28. Matic I, Titlic M, Dikanovic M, Jurjevic M, Jukic I, Tonkic A. Effects of APACHE II score on mechanical ventilation; prediction and outcome. Acta Anaesthesiol Belg 2007, 58:177-183.
29. Ferreira FL, Bota DP, Bross A, Mélot C, Vincent JL. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 2001, 286:1754-1758. 10.1001/jama.286.14.1754, 11594901.
30. Kim HJ, Lee CH, Shin S, Lee JH, Kim YW, Chung HS, Han SK, Shim YS, Kim DK. The impact of nutritional deficit on mortality of in-patients with pulmonary tuberculosis. Int J Tuberc Lung Dis 2010, 14:79-85.
31. Centers for Disease Control and Prevention. , http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5710a2.htm
32. Erbes R, Oettel K, Raffenberg M, Mauch H, Schmidt-loanas M, Lode H. Characteristics and outcome of patients with active pulmonary tuberculosis requiring intensive care. Eur Respir J 2006, 27:1223-1228. 10.1183/09031936.06.00088105, 16481385.
33. Ginsburg AS, Hooper N, Parrish N, Dooley KE, Dorman SE, Booth J, Diener-West M, Merz WG, Bishai WR, Sterling TR. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis 2003, 37:1448-1452. 10.1086/379328, 14614666.
34. Johnson JL, Hadad DJ, Boom WH, Daley CL, Peloquin CA, Eisenach KD, Jankus DD, Debanne SM, Charlebois ED, Maciel E, Palaci M, Dietze R. Early and extended early bactericidal activity of levofloxacin, gatifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006, 10:605-612.
35. Pletz MWR, De Roux A, Roth A, Neumann KH, Mauch H, Lode H. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob Agents Chemother 2004, 48:780-782. 10.1128/AAC.48.3.780-782.2004, 353154, 14982764.
36. Dinçer I, Ergin A, Kocagöz T. The vitro efficacy of beta-lactam and beta-lactamase inhibitors against multi-drug resistant clinical strains of Mycobacterium tuberculosis. Int J Antimicrob Agents 2004, 23:408-411. 10.1016/j.ijantimicag.2003.09.023, 15081094.
37. Wang M, Fitzgerald JM, Richardson K, Marra CA, Cook VJ, Hajek J, Elwood RK, Bowie WR, Marra F. Is the delay in diagnosis of pulmonary tuberculosis related to exposure to fluoroquinolones or any antibiotic?. Int Tuberc Lung Dis 2011, 15:1062-1068.
38. Nasa P, Juneja D, Singh O, Dang R, Arora V, Saxena S. Incidence of bacteremia at the time of ICU admission and its impact on outcome. Indian J Anaesth 2011, 55:594-598. 10.4103/0019-5049.90615, 3249867, 22223904.
39. Yang CH, Huang YF, Wang KF, Chan PC, Chen KJ. Trend of HIV prevalence in Tuberculosis patients in Taiwan, 2001-2008 Poster Presentation at 40th Union World Conference on Lung Health, December 2009 Cancun, Maxico.